In a bold move that could redefine the future of mRNA-driven cancer therapies, German biotech giant BioNTech SE announced Thursday its all-stock acquisition of fellow German firm CureVac NV, valuing the clinical-stage mRNA specialist at approximately $1.25 billion. The deal, a strategic fusion of ambition and expertise, is expected to close later this year pending regulatory and shareholder approvals.

With five heavyweight legal teams steering the transaction, the deal reads like a biotech courtroom drama. BioNTech is advised by Covington & Burling LLP, Hengeler Mueller, and Loyens & Loeff, while Skadden Arps Slate Meagher & Flom LLP and NautaDutilh NV represent CureVac.

An mRNA Merger Two Decades in the Making

This isn’t just another headline-grabbing merger. It’s a collision of two biotech juggernauts whose paths have long run parallel in the high-stakes world of mRNA research. BioNTech, headquartered in Mainz, catapulted into the global spotlight as the co-developer—with Pfizer—of the first COVID-19 vaccine authorized in the United States and beyond.

CureVac, based in Tübingen, once a COVID contender that missed the vaccine finish line, pivoted hard toward platform innovation, manufacturing scale-up, and oncology and infectious disease research.

“This transaction is another building block in BioNTech's oncology strategy and an investment in the future of cancer medicine,” said Dr. Uğur Şahin, BioNTech’s CEO and co-founder.

Shareholders, Strategy, and a Shift in Ownership

Under the terms of the deal, CureVac shareholders will receive BioNTech American depositary shares (ADSs) valued at around $5.46 per CureVac share. However, the final exchange ratio is subject to a collar mechanism tied to BioNTech’s share price. Once the ink is dry, CureVac shareholders are expected to hold 4% to 6% of BioNTech.

Following completion, CureVac will become a wholly owned subsidiary, and BioNTech plans to fully integrate CureVac’s cutting-edge research and production facilities in Tübingen.

Legal Dream Teams and Billion-Dollar Counsel

The legal architecture behind the transaction resembles a biotech summit of elite counsel. Covington's team guiding BioNTech includes partners Jack Bodner, Sibel Yilmaz, and Paul Claydon, alongside associate Laura Bleier. CureVac's legal firepower is led by Holger Hofmeister and Stephan Hutter at Skadden, with Caspar Schmelzer as counsel.

Financial advisory roles were similarly high-caliber: PJT Partners advised BioNTech exclusively, while Goldman Sachs Bank Europe SE counseled CureVac.

The End of Competition, the Birth of Synergy

“For more than two decades, both companies have operated with related ambitions, often tackling challenges from different angles,” said Dr. Alexander Zehnder, CEO of CureVac. “This transaction aims at combining complementary scientific capabilities, proprietary technologies and manufacturing expertise in the mRNA field under one roof.”

The deal underscores an industry-wide momentum: the convergence of scientific talent, proprietary platforms, and manufacturing firepower to dominate the future of personalized medicine and cancer treatment.

With this acquisition, BioNTech is not just buying assets—it's absorbing a legacy, co-opting a rival, and rewriting the next chapter in the mRNA revolution.